Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):522-30.
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):512-21.
Engelborghs S, D'Hooge R, De Deyn PP. Pathophysiology of epilepsy. Acta Neurol Belg. 2000 Dec;100(4):201-13.
Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016 Jan-Feb;16(1):48-61.
Leone MA, Giussani G, Nolan SJ, et al. Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. Cochrane Database Syst Rev. 2016 May 6;(5):CD007144.
Royal College of Obstetricians and Gynaecologists. Epilepsy in pregnancy (Green-top Guideline No.68). Jun 2016 [internet publication].
1. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):522-30.
2. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010 Apr;51(4):676-85.
3. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4):475-82.
4. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):512-21.
5. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981 Aug;22(4):489-501.
6. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989 Jul-Aug;30(4):389-99.
7. Engel J, Jr. Report of the ILAE classification core group. Epilepsia. 2006 Sep;47(9):1558-68.
8. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993 May-Jun;34(3):453-68.
9. Hauser WA, Hesdorffer DC. Epilepsy: frequency, causes and consequences. New York, NY: Demos Publications; 1990.
10. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia. 1991 Jul-Aug;32(4):429-45.
11. Lavados J, Germain I, Morales A, et al. A descriptive study of epilepsy in the district of El Salvador, Chile, 1984-1988. Acta Neurol Scand. 1992 Apr;85(4):249-56.
12. Rwiza HT, Kilonzo GP, Haule J, et al. Prevalence and incidence of epilepsy in Ulanga, a rural Tanzanian district: a community-based study. Epilepsia. 1992 Nov-Dec;33(6):1051-6.
13. Gracia FJ, Loo S, Castillo L, et al. Epidemiology of epilepsy in Guaymi indians from Bocas del Toro province, Republic of Panama. Epilepsia. 1990 Nov-Dec;31(6):718-23.
14. Rao VR, Parko KL. Clinical approach to posttraumatic epilepsy. Semin Neurol. 2015 Feb;35(1):57-63.
15. Salazar AM, Jabbari B, Vance SC, et al. Epilepsy after penetrating head injury. I. Clinical correlates: a report of the Vietnam Head Injury Study. Neurology. 1985 Oct;35(10):1406-14.
16. Annegers JF, Grabow JD, Groover RV, et al. Seizures after head trauma: a population study. Neurology. 1980 Jul;30(7 Pt 1):683-9.
17. Annegers JF, Hauser WA, Coan SP, et al. A population-based study of seizures after traumatic brain injuries. N Engl J Med. 1998 Jan 1;338(1):20-4.
18. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007 May;6(5):421-30.
19. Vecht C, Wilms EB. Seizures in low- and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther. 2010 May;10(5):663-9.
20. Rudà R, Bello L, Duffau H, et al. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol. 2012 Sep;14 Suppl 4:iv55-64.
22. Foy PM, Copeland GP, Shaw MD. The natural history of postoperative seizures. Acta Neurochir (Wien). 1981;57(1-2):15-22.
23. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993 May-Jun;34(3):453-68.
24. Holtkamp M, Beghi E, Benninger F, et al. European Stroke Organisation guidelines for the management of post-stroke seizures and epilepsy. Eur Stroke J. 2017;2(2):103-15.
25. Hauser WA, Morris ML, Heston LL, et al. Seizures and myoclonus in patients with Alzheimer's disease. Neurology. 1986 Sep;36(9):1226-30.
26. Hesdorffer DC, Hauser WA, Annegers JF, et al. Dementia and adult-onset unprovoked seizures. Neurology. 1996 Mar;46(3):727-30.
27. Doose H, Baier WK. Benign partial epilepsy and related conditions: multifactorial pathogenesis with hereditary impairment of brain maturation. Eur J Pediatr. 1989 Dec;149(3):152-8.
28. Treiman DM. Genetics of the partial epilepsies. In: Beck-Mannagetta G, Anderson VE, Doose H, et al., eds. Genetics of the epilepsies. Berlin: Springer-Verlag; 1989:73-82.
29. Tan HJ, Singh J, Gupta R, et al. Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes. Cochrane Database Syst Rev. 2014 Sep 5;(9):CD006779.
30. Wilkins RH. Natural history of intracranial vascular malformations: a review. Neurosurgery. 1985 Mar;16(3):421-30.
31. Bertram E. The relevance of kindling for human epilepsy. Epilepsia. 2007;48 Suppl 2:65-74.
32. Engelborghs S, D'Hooge R, De Deyn PP. Pathophysiology of epilepsy. Acta Neurol Belg. 2000 Dec;100(4):201-13.
33. Nemani VM. Binder DK. Emerging role of gap junctions in epilepsy. Histol Histopathol. 2005 Jan;20(1):253-9.
34. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics. 2007 Jan;4(1):18-61.
35. Nelson KB, Ellenberg JH. Predictors of epilepsy in children who have experienced febrile seizures. N Engl J Med. 1976 Nov 4;295(19):1029-33.
36. Annegers JF, Hauser WA, Shirts SB, et al. Factors prognostic of unprovoked seizures after febrile convulsions. N Engl J Med. 1987 Feb 26;316(9):493-8.
37. Annegers JF, Hauser WA, Beghai E, et al. The risk of unprovoked seizures after encephalitis and meningitis. Neurology. 1988 Sep;38(9):1407-10.
38. Baird RA, Wiebe S, Zunt JR, et al. Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 Apr 9;80(15):1424-9.
39. Shinton RA, Gill JS, Zezulka AV, et al. The frequency of epilepsy preceding stroke. Case-control study in 230 patients. Lancet. 1987 Jan 3;1(8523):11-3.
40. Goulden KJ, Shinnar S, Koller H, et al. Epilepsy in children with mental retardation: a cohort study. Epilepsia. 1991 Sep-Oct;32(5):690-7.
41. College of Emergency Medicine (UK). Guideline for the management of first seizure in the emergency department. Dec 2009 [internet publication].
42. Chen DK, So YT, Fisher RS, et al. Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2005 Sep 13;65(5):668-75.
43. Shukla G, Bhatia M, Vivekanandhan S, et al. Serum prolactin levels for differentiation of nonepileptic versus true seizures: limited utility. Epilepsy Behav. 2004 Aug;5(4):517-21.
44. Salinsky M, Kanter R, Dasheiff RM. Effectiveness of multiple EEGs in supporting the diagnosis of epilepsy: an operational curve. Epilepsia. 1987 Jul-Aug;28(4):331-4.
45. Harden CL, Huff JS, Schwartz TH, et al. Reassessment: neuroimaging in the emergency patient presenting with seizure (an evidence-based review). Neurology. 2007 Oct 30;69(18):1772-80.
46. Gaillard WD, Chiron C, Cross JH, et al; ILAE, Subcommittee for Pediatric Neuroimaging. Guidelines for imaging infants and children with recent-onset epilepsy. Epilepsia. 2009 Sep;50(9):2147-53.
47. American College of Radiology. ACR appropriateness criteria: seizures and epilepsy. 2014 [internet publication].
48. Kuzniecky R, Burgard S, Faught E, et al. Predictive value of magnetic resonance imaging in temporal lobe epilepsy surgery. Arch Neurol. 1993 Jan;50(1):65-9.
49. Boon P, De Reuck J, Drieghe C, et al. Long-term video-EEG monitoring revisited. The value of interictal and ictal video-EEG recording, a follow-up study. Eur Neurol. 1994;34 Suppl 1:33-9.
50. Salamon N, Kung J, Shaw SJ, et al. FDG-PET/MRI coregistration improves detection of cortical dysplasia in patients with epilepsy. Neurology. 2008 Nov 11;71(20):1594-601.
51. Knowlton RC, Lawn ND, Mountz JM, et al. Ictal SPECT analysis in epilepsy: subtraction and statistical parametric mapping techniques. Neurology. 2004 Jul 13;63(1):10-5.
52. Avbersek A, Sisodiya S. Does the primary literature provide support for clinical signs used to distinguish psychogenic nonepileptic seizures from epileptic seizures? J Neurol Neurosurg Psychiatry. 2010 Jul;81(7):719-25.
53. Jankovic J, Lang AE. Movement disorders: diagnosis and assessment. In: Bradley WG, Daroff RB, Fenichel GM, et al, eds. Neurology in clinical practice. Principles of diagnosis and management. 4th ed. Philadelphia, PA: Elsevier; 2004:313-5.
54. Fahn S, Jankovic J. Principles and practice of movement disorders. Philadelphia, PA: Elsevier; 2007:409-33.
55. Bartsch T, Butler C. Transient amnesic syndromes. Nat Rev Neurol. 2013 Feb;9(2):86-97.
56. Kim J, Kwon Y, Yang Y, et al. Clinical experience of modified diffusion-weighted imaging protocol for lesion detection in transient global amnesia: an 8-year large-scale clinical study. J Neuroimaging. 2014 Jul-Aug;24(4):331-7.
57. Scheel M, Malkowsky C, Klingebiel R, et al. Magnetic resonance imaging in transient global amnesia: lessons learned from 198 cases. Clin Neuroradiol. 2012 Dec;22(4):335-40.
58. Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016 Jan-Feb;16(1):48-61.
59. Leone MA, Giussani G, Nolan SJ, et al. Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. Cochrane Database Syst Rev. 2016 May 6;(5):CD007144.
60. Kim LG, Johnson TL, Marson AG, et al; MRC MESS Study Group. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol. 2006 Apr;5(4):317-22.
61. Ramaratnam S, Panebianco M, Marson AG. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2016 Jun 22;(6):CD001909.
62. Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006453.
63. Nevitt SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017 Dec 15;(12):CD011412.
64. Brodie MJ, Perucca E, Ryvlin P, et al; Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007 Feb 6;68(6):402-8.
65. Ben-Menachem E, Sander JW, Stefan H, et al. Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy. Clin Ther. 2008 Jul;30(7):1180-95.
66. Pulman J, Jette N, Dykeman J, et al. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2014 Feb 25;(2):CD001417.
67. Mbizvo GK, Dixon P, Hutton JL, et al. Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD001901.
68. Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: A phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2012 Jul;11(7):579-88.
69. National Institute for Health and Care Excellence. Partial-onset seizures in epilepsy: zonisamide as monotherapy. Apr 2013 [internet publication].
70. National Institute for Health and Care Excellence. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy. Mar 2014 [internet publication].
71. Ben-Menachem E, Mameniškienė R, Quarato PP, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016 Jul 19;87(3):314-23.
72. Lattanzi S, Cagnetti C, Foschi N, et al. Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis. Neurology. 2016 Apr 5;86(14):1344-52.
73. Biton V, Berkovic SF, Abou-Khalil B, et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014 Jan;55(1):57-66.
74. Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015 Dec;56(12):1890-8.
75. Harris JA, Murphy JA. Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain. Ann Pharmacother. 2009 Nov;43(11):1809-17.
76. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007 Jul;48(7):1308-17.
77. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009 Mar;50(3):443-53.
78. Chung S, Sperling MR, Biton V, et al; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010 Jun;51(6):958-67.
79. Chung S, Ben-Menachem E, Sperling MR, et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs. 2010 Dec;24(12):1041-54.
80. Simoens S. Lacosamide as adjunctive therapy for partial-onset epileptic seizures: a review of the clinical and economic literature. Curr Med Res Opin. 2011 Jul;27(7):1329-38.
81. Pulman J, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2014 Mar 12;(3):CD005612.
82. Joshi R, Tripathi M, Gupta P, et al. Effect of clobazam as add-on antiepileptic drug in patients with epilepsy. Indian J Med Res. 2014 Aug;140(2):209-15.
83. Gidal BE, Laurenza A, Hussein Z, et al. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology. 2015 May 12;84(19):1972-80.
84. Arya R, Anand V, Garg SK, et al. Clobazam monotherapy for partial-onset or generalized-onset seizures. Cochrane Database Syst Rev. 2014 Oct 4;(10):CD009258.
85. Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia. 2009 Aug;50(8):1899-909.
86. Wisniewski CS. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with Lennox-Gastaut syndrome. Ann Pharmacother. 2010 Apr;44(4):658-67.
87. Biton V, Krauss G, Vasquez-Santana B, et al. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia. 2011 Feb;52(2):234-42.
88. Verrotti A, Loiacono G, Ballone E, et al. Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis. Pediatr Neurol. 2011 May;44(5):347-9.
89. Hemming K, Maguire MJ, Hutton JL, et al. Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD007302.
90. Xiao Y, Gan L, Wang J, et al. Vigabatrin versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev. 2015 Nov 18;(11):CD008781.
91. Shi LL, Dong J, Ni H, et al. Felbamate as an add-on therapy for refractory partial epilepsy. Cochrane Database Syst Rev. 2017 Jul 18;(7):CD008295.
92. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000 Feb 3;342(5):314-9.
93. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology. 2008 Jan 1;70(1):54-65.
94. Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007 Jan;29(1):26-48.
95. Delahoy P, Thompson S, Marschner IC. Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships. BMC Neurol. 2010 Nov 1;10:104.
96. Baulac M, Leon T, O'Brien TJ, et al. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. Epilepsy Res. 2010 Sep;91(1):10-9.
97. Kwan P, Brodie MJ, Kälviäinen R, et al. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol. 2011 Oct;10(10):881-90.
98. Hauser WA. Epidemiology of seizures in the elderly. In: Rowan AJ, Ramsay RE, eds. Seizures and epilepsy in the elderly. Boston, MA: Butterworth-Heinemann; 1997:7-20.
99. Ensrud KE, Walczak TS, Blackwell TL, et al; Osteoporotic Fractures in Men (MrOS) Study Research Group. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology. 2008 Sep 2;71(10):723-30.
100. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005 Jun 14;64(11):1868-73.
101. Groselj J, Guerrini R, Van Oene J, et al; TOP-INT-51 Investigators' Group. Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. Acta Neurol Scand. 2005 Sep;112(3):144-50.
102. Alsaadi TM, Koopmans S, Apperson M, et al. Levetiracetam monotherapy for elderly patients with epilepsy. Seizure. 2004 Jan;13(1):58-60.
103. Saetre E, Perucca E, Isojärvi J, et al; LAM 40089 Study Group. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia. 2007 Jul;48(7):1292-302.
104. American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Neurology. 1998 Oct;51(4):944-8.
105. Royal College of Obstetricians and Gynaecologists. Epilepsy in pregnancy (Green-top Guideline No.68). Jun 2016 [internet publication].
106. Wyszynski DF, Nambisan M, Surve T, et al; Antiepileptic Drug Pregnancy Registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology. 2005 Mar 22;64(6):961-5.
107. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol. 2004 May;61(5):673-8.
108. Meador KJ, Baker GA, Browning N, et al; NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009 Apr 16;360(16):1597-605.
109. Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes. Neurology. 2009 Jul 14;73(2):133-41.
110. European Medicines Agency. New measures to avoid valproate exposure in pregnancy endorsed. Mar 2018 [internet publication].
111. Harden CL, Pennell PB, Koppel BS, et al; American Academy of Neurology; American Epilepsy Society. Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding. Neurology. 2009 Jul 14;73(2):142-9.
112. Longo B, Forinash AB, Murphy JA. Levetiracetam use in pregnancy. Ann Pharmacother. 2009 Oct;43(10):1692-5.
113. Morrow JI, Hunt SJ, Russell AJ, et al. Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2009 May;80(5):506-11.
114. New South Wales Ministry of Health. Infants and children: acute management of seizures. Feb 2016 [internet publication].
115. Ambrosetto G, Tassinari CA. Antiepileptic drug treatment of benign childhood epilepsy with rolandic spikes: is it necessary? Epilepsia. 1990 Nov-Dec;31(6):802-5.
116. Souverein PC, Webb DJ, Weil JG, et al. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology. 2006 May 9;66(9):1318-24.
117. Wiebe S, Warren T, Blume JP, et al; Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001 Aug 2;345(5):311-8.
118. Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg. 2011 Dec;115(6):1248-55.
119. Panebianco M, Rigby A, Weston J, et al. Vagus nerve stimulation for partial seizures. Cochrane Database Syst Rev. 2015 Apr 3;(4):CD002896.
120. Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia. 2010 May;51(5):899-908.
121. US Food and Drug Administration. RNS® System - P100026. Jan 2015 [internet publication].
122. Bergey GK, Morrell MJ, Mizrahi EM, et al. Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. Neurology. 2015 Feb 24;84(8):810-7.
123. Heck CN, King-Stephens D, Massey AD, et al. Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS System Pivotal trial. Epilepsia. 2014 Mar;55(3):432-41.
124. Morrell MJ; RNS System in Epilepsy Study Group. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. Neurology. 2011 Sep 27;77(13):1295-304.
125. Freeman JM, Kossoff EH, Freeman JB, et al. The ketogenic diet: a treatment for children and others with epilepsy. New York, NY: Demos Medical Publishing; 2006.
126. Martin K, Jackson CF, Levy RG, et al. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev. 2016 Feb 9;(2):CD001903.
127. Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012 Feb 16;366(7):591-600.
128. Dewolfe JL, Szaflarski JP. Levetiracetam use in the critical care setting. Front Neurol. 2013 Aug 23;4:121.
129. Glauser T, Ben-Menachem E, Bourgeois B, et al; ILAE Subcommission on AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013 Mar;54(3):551-63.
130. Werhahn KJ, Trinka E, Dobesberger J, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia. 2015 Mar;56(3):450-9.
131. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009 Apr 16;360(16):1597-605.
132. Morris GL 3rd, Gloss D, Buchhalter J, et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 Oct 15;81(16):1453-9.
133. Faught E, Holmes GL, Rosenfeld WE, et al. Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures. Neurology. 2008 Nov 11;71(20):1586-93.
134. Halford JJ, Ben-Menachem E, Kwan P, et al. A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures. Epilepsia. 2011 Apr;52(4):816-25.
135. Baulac M, Klement S; Losigamone Study Group. Efficacy and safety of losigamone in partial seizures: a randomized double-blind study. Epilepsy Res. 2003 Aug;55(3):177-89.
136. Xiao Y, Luo M, Wang J, et al. Losigamone add-on therapy for focal epilepsy. Cochrane Database Syst Rev. 2018 Jan 22;(1):CD009324.
137. Yang X, Meehan AL, Rothman SM, et al. Seletracetam enhances short term depression in vitro. Epilepsy Res. 2015 Nov;117:17-22.
138. Pollard JR, French J. Antiepileptic drugs in development. Lancet Neurol. 2006 Dec;5(12):1064-7.
139. Strozzi I, Nolan SJ, Sperling MR, et al. Early versus late antiepileptic drug withdrawal for people with epilepsy in remission. Cochrane Database Syst Rev. 2015 Feb 11;(2):CD001902.
140. Harden C, Tomson T, Gloss D, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2017 Apr 25;88(17):1674-80.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台